Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572400 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2CYP1A2CYP3A4THPO | |
| SCHEMBL1572395 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2CYP1A2CYP3A4THPO | |
| SCHEMBL1571502 | 0.91 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL1571504 | 0.91 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL1571506 | 0.91 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL1765092 | 0.90 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL1571725 | 0.90 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL1571724 | 0.90 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL1571663 | 0.90 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL1571793 | 0.87 | HCRTR1 (0.45) | HCRTR1HCRTR2CYP1A2CYP3A4THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288435-B2 | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-26 | — | — | US | disclosed |
| EP-2094690-B1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124636-A1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CNR1 | HCRTR1 2/4885HCRTR2 1/4885CYP1A2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.